GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Institutional Ownership

NeoImmuneTech (XKRX:950220) Institutional Ownership : 0.21% (As of May. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NeoImmuneTech's institutional ownership is 0.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NeoImmuneTech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NeoImmuneTech's Float Percentage Of Total Shares Outstanding is 0.00%.


NeoImmuneTech Institutional Ownership Historical Data

The historical data trend for NeoImmuneTech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Institutional Ownership Chart

NeoImmuneTech Historical Data

The historical data trend for NeoImmuneTech can be seen below:

2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31
Institutional Ownership 14.60 12.70 12.70 2.02 0.71 0.50 0.50 0.21 0.21 0.21

NeoImmuneTech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


NeoImmuneTech (XKRX:950220) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines